Navigation Links
Lamotrigine is One of the Most Commonly Prescribed Drugs Among Newly Diagnosed Bipolar Disorder Patients in the United States
Date:10/23/2013

BURLINGTON, Mass., Oct. 23, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through analysis of U.S. longitudinal patient-level claims data, antiepileptic drugs (AEDs), atypical antipsychotics and selective serotonin reuptake inhibitors capture the largest patient shares among all therapies assessed in newly diagnosed bipolar disorder patients across all three lines of therapy. Although no single agent from any of these drug classes was shown to dominate first-line treatment of newly diagnosed bipolar disorder patients, the AED lamotrigine (GlaxoSmithKline's Lamictal, generics) led other individual agents with nearly 20 percent of first-line patient share. According to thought leaders interviewed by Decision Resources, lamotrigine is considered to be beneficial for preventing and treating bipolar depression, one of the more challenging aspects of treating bipolar disorder.

The report Treatment Algorithms in Bipolar Disorder finds that among newly diagnosed patients, Abilify (Bristol-Myers Squibb/Otsuka) captured the highest first-line patient share within the atypical antipsychotic drug class, despite the availability of multiple generically available agents. Abilify's high patient share among agents in this class is likely due to relatively favorable reimbursement status, a more favorable tolerability profile than other atypical antipsychotics and approval to treat multiple psychiatric indications, which can contribute to physician awareness and preference.

The report also finds that, together, quetiapine products (AstraZeneca's Seroquel, generics and AstraZeneca's Seroquel XR) claimed the highest percentage of patient share within the atypical antipsychotic class among recently treated bipolar disorder patients. Combined, these agents earned over 12 percent patient share during the key therapy period analyzed. Bipolar disorder patients recently treated with Seroquel XR progress to the drug from quetiapine at a greater rate than those recently treated with quetiapine who progress from Seroquel XR. Seroquel XR is approved to treat multiple psychiatric indications, is dosed once daily and is generally subject to fewer market access hurdles than other branded atypical antipsychotics. These factors all contribute to recently treated patients' preferential progression from quetiapine to Seroquel XR.

"Our study findings indicate that quetiapine products are popular options for the treatment of bipolar disorder, and this aligns with the opinions of interviewed experts," said Decision Resources Senior Business Insights Analyst Alana Simorellis, Ph.D. "Quetiapine's efficacy in treating bipolar depression, an area of high unmet need in the bipolar disorder market, gives the molecule an advantage in physician prescribing over most other atypical antipsychotics. In addition, quetiapine and quetiapine XR are approved for all phases of bipolar disorder treatment and are viewed by thought leaders as efficacious options for insomnia and anxiety."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Though Over One-Third of Rheumatologists Have Prescribed Xeljanz for Their Rheumatoid Arthritis Patients, Physicians are Still Concerned With the Drugs Limited Post-Marketing Experience and Risks of Infection and Malignancy
2. House Bill Preserves Medicare Patient Access to Doctor-Prescribed Equipment Says AAHomecare
3. New Research: Nationwide Report Shows Prescribed Drugs Not Detected in More Than One-Third of Pain Patient Samples
4. At One Month Post-Launch, Nearly One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Xofigo to Their Prostate Cancer Patients
5. At One Month Post-Launch, Nearly a Quarter of Surveyed U.S. Oncologists Have Prescribed Tafinlar for Malignant Melanoma, Compared to 15 Percent Who Used Mekinist
6. Ophthalmic Drugs: World Market Prospects 2012-2022
7. Antithrombotic/Anticoagulant Drugs: World Market 2012-2022
8. INTAC™ Technology Combats Misuse of Extended Release Drugs
9. Contract Research Organizations Set to Experience Rapid Growth as Development Costs for New Drugs Continue to Rise
10. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
11. Bilcare and CSIR to Partner on nonClonableID Technology for Authentication of Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Israel , March 27, 2017 ... oncology and immunology, announced today that AGI-134, an immunotherapy for ... acquisition of Agalimmune Ltd., will be featured at the upcoming ... in Washington, DC to be held ... ...
(Date:3/27/2017)... FRANCISCO , March 27, 2017 ... expected to reach USD 16.0 billion by 2025, according ... The growing prevalence of chronic diseases is anticipated to ... chemistry analyzers, which thereby widens the scope for growth ... geriatric and bariatric population, which is highly susceptible to ...
(Date:3/27/2017)...  Impax Laboratories, Inc. (NASDAQ: IPXL)today announced that its ... as Impax,s President and Chief Executive Officer and ... 2017. Mr. Bisaro will succeed J. Kevin Buchi ... Executive Officer since December of 2016. ... Mr. Bisaro, 56, is an accomplished global business leader ...
Breaking Medicine Technology:
(Date:3/27/2017)... , ... March 27, 2017 , ... The Anaheim Hills ... customers. First National Capital has added 10 new sales professionals over the past 6 ... positions by 15 additional new hires over the course of 2017. , “This ...
(Date:3/27/2017)... ... March 27, 2017 , ... Golden Triangle Emergency Center will ... April 3rd to commemorate the two-year anniversary of the facility. The event will ... two great years while also familiarizing themselves with the facility. , In the ...
(Date:3/26/2017)... Columbus, Ohio (PRWEB) , ... March 26, 2017 ... ... 100 doctors worldwide to receive the RealSelf 100 Award, a prestigious award honoring ... elective cosmetic procedures and to find and connect with doctors and clinics. , ...
(Date:3/24/2017)... ... 2017 , ... Vighter established its NAEMT Authorized Training Center ... Trauma Life Support (PHTLS) course scholarships to four medics assigned to the Minnesota ... cooperation with the American College of Surgeons to promote critical thinking in addressing ...
(Date:3/24/2017)... ... 2017 , ... The Radiology Business Management Association (RBMA) has named ... in their 12th year, are among the most prestigious in radiology marketing because a ... were retooled to recognize achievements in both large budget (over $5,000) and small budget ...
Breaking Medicine News(10 mins):